243 related articles for article (PubMed ID: 24681657)
1. The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patients.
Twersky RS; Goel V; Narayan P; Weedon J
Anesth Analg; 2014 May; 118(5):938-44. PubMed ID: 24681657
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Steely AM; Callas PW; Bertges DJ;
J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
[TBL] [Abstract][Full Text] [Related]
3. Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis.
Ling Q; Gu Y; Chen J; Chen Y; Shi Y; Zhao G; Zhu Q
BMC Anesthesiol; 2018 Feb; 18(1):26. PubMed ID: 29482507
[TBL] [Abstract][Full Text] [Related]
4. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis.
Capoulade R; Clavel MA; Mathieu P; Côté N; Dumesnil JG; Arsenault M; Bédard E; Pibarot P
Eur J Clin Invest; 2013 Dec; 43(12):1262-72. PubMed ID: 24117162
[TBL] [Abstract][Full Text] [Related]
5. A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan.
Abughosh SM; Wang X; Serna O; Henges C; Masilamani S; Essien EJ; Chung N; Fleming M
J Manag Care Spec Pharm; 2016 Jan; 22(1):63-73. PubMed ID: 27015053
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery.
Hollmann C; Fernandes NL; Biccard BM
Anesth Analg; 2018 Sep; 127(3):678-687. PubMed ID: 29381513
[TBL] [Abstract][Full Text] [Related]
7. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
[TBL] [Abstract][Full Text] [Related]
8. Influence of angiotensin-converting enzyme inhibitors on hypotension after anesthetic induction: is the preoperative discontinuation of this drug necessary?
da Costa VV; Caldas AC; Nunes LG; Beraldo PS; Saraiva RA
Rev Bras Anestesiol; 2009; 59(6):704-15. PubMed ID: 20011860
[TBL] [Abstract][Full Text] [Related]
9. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
10. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period.
Rosenman DJ; McDonald FS; Ebbert JO; Erwin PJ; LaBella M; Montori VM
J Hosp Med; 2008 Jul; 3(4):319-25. PubMed ID: 18698608
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
12. The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial.
Misra S; Parida S; Sahajanandan R; Behera BK; Senthilnathan M; Mariappan R; Chandy TT;
Trials; 2022 Aug; 23(1):670. PubMed ID: 35978368
[TBL] [Abstract][Full Text] [Related]
13. The effect of angiotensin-converting enzyme inhibitor on hemodynamic instability in patients undergoing cardiopulmonary bypass: results of a dose-comparison study.
Shahzamani M; Yousefi Z; Frootaghe AN; Jafarimehr E; Froughi M; Tofighi F; Azadani AN; Pourhoseingholi MA; Azadani PN
J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):185-91. PubMed ID: 19721131
[TBL] [Abstract][Full Text] [Related]
14. Memory is preserved in older adults taking AT1 receptor blockers.
Ho JK; Nation DA;
Alzheimers Res Ther; 2017 Apr; 9(1):33. PubMed ID: 28446207
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
16. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
17. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.
Ahad A; Al-Mohizea AM; Al-Jenoobi FI; Aqil M
Drug Deliv; 2016; 23(2):579-90. PubMed ID: 25065883
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.
Bauer A; Schreinlechner M; Sappler N; Dolejsi T; Tilg H; Aulinger BA; Weiss G; Bellmann-Weiler R; Adolf C; Wolf D; Pirklbauer M; Graziadei I; Gänzer H; von Bary C; May AE; Wöll E; von Scheidt W; Rassaf T; Duerschmied D; Brenner C; Kääb S; Metzler B; Joannidis M; Kain HU; Kaiser N; Schwinger R; Witzenbichler B; Alber H; Straube F; Hartmann N; Achenbach S; von Bergwelt-Baildon M; von Stülpnagel L; Schoenherr S; Forer L; Embacher-Aichhorn S; Mansmann U; Rizas KD; Massberg S;
Lancet Respir Med; 2021 Aug; 9(8):863-872. PubMed ID: 34126053
[TBL] [Abstract][Full Text] [Related]
19. Surgery and discontinuation of angiotensin converting enzyme inhibitors: current perspectives.
Bradic N; Povsic-Cevra Z
Curr Opin Anaesthesiol; 2018 Feb; 31(1):50-54. PubMed ID: 29206698
[TBL] [Abstract][Full Text] [Related]
20. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
